Inceptor Bio
Morrisville, US · Founded 2020 · North Carolina LLC · 20 employees on LinkedIn · 2 known investors
Find your way into Inceptor Bio
229 people in our graph share verified history with the Inceptor Bio team — schools, employers, funds. One of them is your warm intro.
David Phuunlockedknows Jason Lawrence · together at Golden Gate University
×3knows the team · via Freie Universität Berlin
×8knows the team · via Golden Gate University
Inceptor Bio is a clinical-stage biotechnology company developing cell therapies for cancer, focused on solid tumors. Its OUTLAST platform reprograms T cells during manufacturing to withstand the tumor microenvironment, and its lead candidate is IB-T101.
Founders & leadership
JL
Jason LawrenceinVice President Finance2021–2026Jason Lawrence is Executive Officer at Inceptor Bio, a clinical-stage biotechnology company developing cell therapies for solid tumors. He brings experience in financial leadership for biotech and life sciences companies, with expertise in capital raises, M&A, financial planning and analysis, SEC reporting, and operational functions including HR, IT, and supply chain.
MS
Matthias SchroffinChief Executive OfficerExecutive officer and director at Inceptor Bio, a clinical-stage cell therapy company developing treatments for solid tumors. Schroff has over 17 years of experience in biotechnology leadership across immuno-oncology, including roles developing capabilities in manufacturing and clinical advancement.
AS
Abraham S. MaingiExecutive
SM
DM
David Michael JohnstonNamed on SEC filing
Board
MB
Mark BamforthinBoard directorGeneral Partner, KAMRA I Investment Committee Member at Kineticos Life Sciences
ES
Elizabeth SmithBoard director
GF
DH
MG
Mark GilbertBoard directorStrategic Advisor at Kineticos Life Sciences
Investors · 2
Also in the syndicate · 1
Kineticos Ventureslead
Reported raises · per SEC filings
Form D private placements$65.7M disclosed across 5 rounds · 2020–2025
▶$3.3MraisedJan 2025 · 10 investors · BiotechnologyRule 506(b)
▶$3.3MraisedJan 2025 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Abraham S. MaingiExecutive Officer
- Elizabeth SmithDirector
- Jason LawrenceExecutive Officer
- Derek HenneckeDirector
- Matthias SchroffExecutive Officer, Director
- Shailesh MaingiDirector
- George FotiadesDirector
- Mark GilbertDirector
- Offering amount
- $3.4M
- Amount sold
- $3.3M
- First sale
- Jan 2025
- Incorporated
- Limited Liability Company, North Carolina, 2020
- Federal exemptions
- 06b
▶$15.9MraisedJul 2024 · 13 investors · BiotechnologyRule 506(b)
▶$15.9MraisedJul 2024 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Elizabeth SmithDirector
- Shailesh MaingiDirector
- George FotiadesDirector
- Derek HenneckeDirector
- Mark GilbertDirector
- Jason LawrenceExecutive Officer
- Matthias SchroffExecutive Officer, Director
- Abraham S. MaingiExecutive Officer
- Offering amount
- $15.9M
- Amount sold
- $15.9M
- First sale
- Oct 2022
- Incorporated
- Limited Liability Company, North Carolina, 2020
- Federal exemptions
- 06b
▶$37.7MraisedMar 2022 · 9 investors · BiotechnologyRule 506(b)
▶$37.7MraisedMar 2022 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David Michael JohnstonDirector
- Shailesh MaingiExecutive Officer, Director, Promoter
- Mark BamforthDirector
- Jason LawrenceExecutive Officer
- Matthew John HainesExecutive Officer
- Derek HenneckeDirector
- Abraham Surinder MaingiExecutive Officer, Director
- Michael NicholsonExecutive Officer
- Offering amount
- $60.8M
- Amount sold
- $37.7M
- First sale
- Feb 2022
- Incorporated
- Limited Liability Company, North Carolina, 2020
- Federal exemptions
- 06b
▶$5.5MraisedJul 2021 · 20 investors · BiotechnologyRule 506(b)
▶$5.5MraisedJul 2021 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David Michael JohnstonDirector
- Abraham Surinder MaingiExecutive Officer, Director
- Shailesh MaingiExecutive Officer, Director, Promoter
- Mark BamforthDirector
- Derek HenneckeDirector
- Offering amount
- $18.1M
- Amount sold
- $5.5M
- First sale
- Jul 2021
- Incorporated
- Limited Liability Company, North Carolina, 2020
- Federal exemptions
- 06b, 3C, 3C.1
▶$3.3MraisedSep 2020 · 6 investors · BiotechnologyRule 506(b)
▶$3.3MraisedSep 2020 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Abraham Surinder MaingiExecutive Officer, Director
- Shailesh MaingiPromoter
- Offering amount
- $3.3M
- Amount sold
- $3.3M
- First sale
- Apr 2020
- Incorporated
- Limited Liability Company, North Carolina, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlap
Companies competing with Inceptor Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Inceptor Bio do?
- Inceptor Bio is a clinical-stage biotechnology company developing cell therapies for cancer, focused on solid tumors. Its OUTLAST platform reprograms T cells during manufacturing to withstand the tumor microenvironment, and its lead candidate is IB-T101.
- Who are Inceptor Bio's investors?
- Inceptor Bio's investors include Kineticos Disruptor.
- How much funding has Inceptor Bio raised?
- Inceptor Bio has disclosed $65.7M raised across 5 rounds.
- Where is Inceptor Bio headquartered?
- Inceptor Bio is headquartered in Morrisville, US.